Dynamic regulation of circulating endotrophin by changes in fat mass in humans.

MetabolismJun 19, 2026 (epub)
Clinical ResearchEndocrinologyInternal Medicine (General)

Rodrigo Fernández-Verdejo, Dawei Bu, Ningyan Zhang et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial investigated the relationship between short-term changes in fat mass and circulating endotrophin levels in 73 healthy adults. Results indicated that changes in fat mass were positively associated with changes in circulating endotrophin, with an unstandardized B-coefficient of 0.76 ng/mL/kg (P < 0.001).

Key findings

  • Changes in fat mass ranged from -11.0 to +7.0 kg.
  • Circulating endotrophin increased by 0.76 ng/mL/kg with fat mass changes.
  • Endotrophin mediated 15% of the effect of fat mass on total cholesterol.

Why it matters

Understanding the dynamics of circulating endotrophin in relation to fat mass changes can provide insights into metabolic health and potential therapeutic targets for obesity-related conditions.

Source

PubMed · PMID 42320555

Published in Metabolism. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.